7SD5
 
 | | Crystallographic structure of neutralizing antibody 10-40 in complex with SARS-CoV-2 spike receptor binding domain | | Descriptor: | 10-40 Heavy chain, 10-40 Light chain, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... | | Authors: | Reddem, E.R, Casner, R.G, Shapiro, L. | | Deposit date: | 2021-09-29 | | Release date: | 2022-04-27 | | Last modified: | 2023-10-18 | | Method: | X-RAY DIFFRACTION (1.53 Å) | | Cite: | An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses.
Sci Transl Med, 14, 2022
|
|
7SI2
 | |
6B5T
 | | Structure of PfCSP peptide 29 with human antibody CIS42 | | Descriptor: | AMMONIUM ION, CIS42 Fab Heavy chain, CIS42 Fab Light chain, ... | | Authors: | Pancera, M, Weidle, C. | | Deposit date: | 2017-09-29 | | Release date: | 2018-03-21 | | Last modified: | 2018-04-25 | | Method: | X-RAY DIFFRACTION (2.222 Å) | | Cite: | A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite.
Nat. Med., 24, 2018
|
|
6BP2
 | | Therapeutic human monoclonal antibody MR191 bound to a marburgvirus glycoprotein | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Envelope glycoprotein, Envelope glycoprotein GP2, ... | | Authors: | King, L.B, Fusco, M.L, Flyak, A.I, Ilinykh, P.A, Huang, K, Gunn, B, Kirchdoerfer, R.N, Hastie, K.M, Sangha, A.K, Meiler, J, Alter, G, Bukreyev, A, Crowe, J.E.J, Saphire, E.O. | | Deposit date: | 2017-11-21 | | Release date: | 2018-01-17 | | Last modified: | 2023-10-04 | | Method: | X-RAY DIFFRACTION (3.172 Å) | | Cite: | The Marburgvirus-Neutralizing Human Monoclonal Antibody MR191 Targets a Conserved Site to Block Virus Receptor Binding.
Cell Host Microbe, 23, 2018
|
|
6B5O
 | | Structure of PfCSP peptide 29 with human protective antibody CIS43 | | Descriptor: | CIS43 Fab Heavy chain, CIS43 Fab Light chain, PfCSP peptide 29: ASN-PRO-ASN-ALA-ASN-PRO-ASN-ALA-ASN | | Authors: | Pancera, M, Weidle, C. | | Deposit date: | 2017-09-29 | | Release date: | 2018-03-21 | | Last modified: | 2018-04-25 | | Method: | X-RAY DIFFRACTION (2.194 Å) | | Cite: | A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite.
Nat. Med., 24, 2018
|
|
8TNL
 | |
1CT8
 | | CATALYTIC ANTIBODY 7C8 COMPLEX | | Descriptor: | 7C8 FAB FRAGMENT; LONG CHAIN, 7C8 FAB FRAGMENT; SHORT CHAIN, SULFATE ION, ... | | Authors: | Gigant, B, Tsumuraya, T, Fujii, I, Knossow, M. | | Deposit date: | 1999-08-20 | | Release date: | 1999-11-10 | | Last modified: | 2011-07-13 | | Method: | X-RAY DIFFRACTION (2.2 Å) | | Cite: | Diverse structural solutions to catalysis in a family of antibodies.
Structure Fold.Des., 7, 1999
|
|
7KI6
 | |
7KI4
 | |
6WN1
 | |
8C2R
 | | SARS-CoV2 Omicron BA.1 spike in complex with CAB-A17 antibody | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, CAB-A17 antibody (HC), ... | | Authors: | Das, H, Hallberg, B.M. | | Deposit date: | 2022-12-22 | | Release date: | 2024-05-22 | | Method: | ELECTRON MICROSCOPY (2.56 Å) | | Cite: | SARS-CoV-2 omicron Spike (RBD) in complex with CAB-A17 antibody
To Be Published
|
|
6WNO
 | |
6WOZ
 | |
7SQ1
 | | BG505.MD39TS Env trimer in complex with Fab from antibody C05 | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, C05 Fab Light chain, ... | | Authors: | Moore, A, Du, J, Xu, Z, Walker, S, Kulp, D.W, Pallesen, J. | | Deposit date: | 2021-11-04 | | Release date: | 2022-06-22 | | Last modified: | 2022-12-07 | | Method: | ELECTRON MICROSCOPY (3.8 Å) | | Cite: | Induction of tier-2 neutralizing antibodies in mice with a DNA-encoded HIV envelope native like trimer.
Nat Commun, 13, 2022
|
|
8DY6
 | | Vaccine elicited Antibody MU89+S27Y bound to CH848.D949.10.17_N133D_N138T.DS.SOSIP.664 HIV-1 Env trimer | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... | | Authors: | Stalls, V, Acharya, P. | | Deposit date: | 2022-08-03 | | Release date: | 2023-04-19 | | Last modified: | 2024-05-22 | | Method: | ELECTRON MICROSCOPY (4.32 Å) | | Cite: | Mutation-guided vaccine design: A process for developing boosting immunogens for HIV broadly neutralizing antibody induction.
Cell Host Microbe, 32, 2024
|
|
6MZJ
 | | Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer, 2 Fabs bound, sharpened map | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, 426c DS-SOSIP D3, ... | | Authors: | Borst, A.J, Weidle, C.E, Gray, M.D, Frenz, B, Snijder, J, Joyce, M.G, Georgiev, I.S, Stewart-Jones, G.B.E, Kwong, P.D, McGuire, A.T, DiMaio, F, Stamatatos, L, Pancera, M, Veesler, D. | | Deposit date: | 2018-11-05 | | Release date: | 2018-11-14 | | Last modified: | 2020-07-29 | | Method: | ELECTRON MICROSCOPY (4.8 Å) | | Cite: | Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer and a glycosylated HIV-1 gp120 core.
Elife, 7, 2018
|
|
5MO9
 | |
7E9B
 | |
6WM9
 | |
4LLD
 | | Structure of wild-type IgG1 antibody heavy chain constant domain 1 and light chain lambda constant domain (IgG1 CH1:Clambda) at 1.19A | | Descriptor: | Ig gamma-1 chain C region, Ig lambda-2 chain C region | | Authors: | Pustilnik, A, Lewis, S.M, Wu, X, Sereno, A, Huang, F, Guntas, G, Leaver-Fay, A, Smith, E.M, Ho, C, Hansen-Estruch, C, Chamberlain, A.K, Truhlar, S.M, Kuhlman, B, Demarest, S.J, Atwell, S. | | Deposit date: | 2013-07-09 | | Release date: | 2014-01-29 | | Last modified: | 2023-09-20 | | Method: | X-RAY DIFFRACTION (1.19 Å) | | Cite: | Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface.
Nat.Biotechnol., 32, 2014
|
|
7E3K
 | | Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants | | Descriptor: | 13G9 heavy chain, 13G9 light chain, 2-acetamido-2-deoxy-beta-D-glucopyranose, ... | | Authors: | Guo, H, Li, T, Liu, F, Gao, Y, Ji, X, Yang, H. | | Deposit date: | 2021-02-09 | | Release date: | 2021-09-15 | | Last modified: | 2022-03-02 | | Method: | ELECTRON MICROSCOPY (3.9 Å) | | Cite: | Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants.
Nat Commun, 12, 2021
|
|
5CD3
 | | Structure of immature VRC01-class antibody DRVIA7 | | Descriptor: | DRVIA7 Heavy Chain, DRVIA7 Light Chain | | Authors: | Kong, L, Wilson, I.A. | | Deposit date: | 2015-07-02 | | Release date: | 2016-04-06 | | Last modified: | 2018-09-05 | | Method: | X-RAY DIFFRACTION (2.9 Å) | | Cite: | Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor.
Immunity, 44, 2016
|
|
4Q6I
 | | Crystal structure of murine 2D5 Fab, a potent anti-CD4 HIV-1-neutralizing antibody in complex with CD4 | | Descriptor: | Heavy chain of murine 2D5 Fab, Light chain of murine 2D5 Fab, T-cell surface glycoprotein CD4 | | Authors: | Boyington, J.C, Nabel, G.J, Mascola, J.R. | | Deposit date: | 2014-04-22 | | Release date: | 2014-07-23 | | Method: | X-RAY DIFFRACTION (3.65 Å) | | Cite: | Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor.
Sci Transl Med, 6, 2014
|
|
5CGY
 | |
4P2C
 | | Complex of Shiga toxin 2e with a neutralizing single-domain antibody | | Descriptor: | Nanobody 1, Anti-F4+ETEC bacteria VHH variable region, Shiga toxin 2e, ... | | Authors: | Lo, A.W.H, Moonens, K, De Kerpel, M, Brys, L, Pardon, E, Remaut, H, De Greve, H. | | Deposit date: | 2014-03-03 | | Release date: | 2014-07-30 | | Last modified: | 2023-12-27 | | Method: | X-RAY DIFFRACTION (2.818 Å) | | Cite: | The Molecular Mechanism of Shiga Toxin Stx2e Neutralization by a Single-domain Antibody Targeting the Cell Receptor-binding Domain.
J.Biol.Chem., 289, 2014
|
|
